HOFSETH BIOCARE ASA: årsregnskap 2024 vs 2023
Grew 22% on revenue, fresh owner capital
approved 2025-04-11; registry 2025-07-30; journal 2025 589883
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for HOFSETH BIOCARE ASA. Revenue 218.4k NOK → 267.0k NOK (+22.3%). Net result -93.00m NOK → -97.90m NOK. Equity 74.61m NOK → 120.42m NOK.
On the constructive side: revenue rose; equity strengthened; cash rose. Pressures included: operating result weakened; net result weakened; current ratio dropped below 1×.
Also worth watching: payroll increased; cogs fell; book investments changed. All figures are taken from the published annual accounts for HOFSETH BIOCARE ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 218.4k NOK to 267.0k NOK (+22.3% YoY). Calculated
-
↑
Equity strengthened
Book equity 74.61m NOK → 120.42m NOK (equity ratio 18.8% → 31.9%). Calculated
-
↑
Cash rose
Bank deposits 22.75m NOK → 23.23m NOK (+2.1% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 74.61m NOK → 120.42m NOK (+45.81m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result -86.44m NOK → -88.43m NOK (op. margin -39577.8% → -33115.5%). Calculated
-
↓
Net result weakened
Net result -93.00m NOK → -97.90m NOK (net margin -42577.1% → -36662.3%). Calculated
-
↓
Current ratio dropped below 1×
Current ratio 638.98× → 0.00× — short-term liabilities now exceed liquid/current assets on the published lines. Calculated
Things to notice
-
·
Payroll increased
Salary cost 51.66m NOK → 60.30m NOK (23651% → 22584% of revenue). Calculated
-
·
COGS fell
COGS / varekostnad 6168537000.15bn NOK → 4 NOK (-100.0% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 44.70m NOK → 59.56m NOK. Reported fact